Please assess the completion status of the following clinical trial:

Trial Title: Random-start Ovarian Stimulation in Egg-donors (ROSE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women~* 18-35 years old~* FSH levels \< 10 IU/liter~* Antral follicle count (AFC) \> 10~* Regular cycles~* Body Mass Index (BMI) \< 28~* Signed informed consent~Exclusion Criteria:~* Polycystic ovary syndrome (PCOS) patients~* Allergy to gonadotrophins~* Concomitant participation in other trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Random start ovarian stimulation (Type: EXPERIMENTAL): Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~* Random start ovarian stimulation~* Gonadotrophins: Urinary FSH 150-225 IU/d~* GnRH antagonists: Cetrorelix 0,25 mg/d~* GnRH agonist for triggering: Triptorelin 0,2 mg single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).